88343-63-9

Basic information

• Product Name: 1-Hexanone, 6-phenyl-1-(2-thienyl)-
• CAS NO: 88343-63-9
• Molecular Formula: C16H18OS
• Molecular Weight: 258.384
• Mol File: 88343-63-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-Hexanone, 6-phenyl-1-(2-thienyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Hexanone, 6-phenyl-1-(2-thienyl)-(88343-63-9)
• EPA Substance Registry System: 1-Hexanone, 6-phenyl-1-(2-thienyl)-(88343-63-9)

Safety Data

• Hazardous Substances Data: 88343-63-9(Hazardous Substances Data)

Upstream product

• 188290-36-0 thiophene 
• 5581-75-9 6-phenylhexanic acid 
• 21389-46-8 6-phenylhexanoyl chloride 

Downstream Products

• 88336-93-0 methyl 15-(p-iodophenyl)-3(RS)-methylpentadecanoate 
• 88336-88-3 Methyl 15-Phenyl-3(R,S)-methylpentadecanoate 
• 116754-87-1 15‐(4‐iodophenyl)‐3‐methylpentadecanoic acid 
• 116754-80-4 15-Phenyl-3(R,S)-methylpentadecanoic Acid 
• 1027476-25-0 3,3-Dimethyl-1-morpholin-4-yl-5-[5-(6-phenyl-hexyl)-thiophen-2-yl]-pentan-1-one 
• 104426-53-1 3,3-Dimethyl-5-[5-(6-phenyl-hexyl)-thiophen-2-yl]-pentanoic acid 
• 88336-90-7 2-[3(RS)-methyl-1-oxo-5-hydroxypentanoyl]-5-(6-phenylhexyl)thiophene 
• 88336-91-8 2-(3(R,S)-Methyl-4-carboxybutyl)-5-(6-phenylhexyl)-thiophene 
• 88336-89-4 2-(6-Phenylhexyl)thiophene 

Relevant articles and documents

Amino derivatives of phenyl alkyl thiophene as inhibitors of bone resorption. Structure-activity relationship

Metabolism of arachidonic acid through the 5-lipoxygenase (LO) pathway generates compounds that stimulate osteoclastic bone resorption; since LO metabolites might play a role in bone loss due to excessive resorption it was tried to develop a series of antiresorptive agents starting from an already known LO inhibitor. Of the 35 compounds synthesized, 11 strongly inhibited (10 μmol/l) retinoic acid-induced bone resorption in cultured mouse calvariae; they were also tested for their effect on LO activity using rat peritoneal neutrophils, but no correlation could be drawn between inhibition of LO and bone resorption. Other pathways, still to be identified, must therefore be targeted by these compounds even though LO inhibition might contribute to their effects on bone. Two compounds selected for further studies were found active on parathyroid hormone-induced osteolysis, while they had no effect on basal resorption; they must, therefore, act at some key point in the process of activation of osteoclastic resorption. This series of compounds may represent a new way for the treatment of bone loss due to excessive resorption.